Navigation Links
Pre-Market Analysis: MannKind, Galena Biopharma, Ariad Pharma, and Novavax
Date:8/2/2013

LONDON, August 2, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

On Thursday, August 1, 2013, shares in biotechnology companies ended mostly higher, tracking the broader market which also finished high on the back of positive US economic statistics. The major movers in the industry included MannKind Corporation (NASDAQ: MNKD), Galena Biopharma Inc. (NASDAQ: GALE), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), and Novavax Inc. (NASDAQ: NVAX). All these companies are tracked by AAAResearchReports.com. Free technical research on MNKD, GALE, ARIA, and NVAX can be downloaded upon sign up at:

http://www.aaaresearchreports.com/register/  

Shares in MannKind Corporation rallied on Thursday, extending their gains from previous trading sessions. The company's shares hit a 52-week high of $8.25 before finishing the day 4.15% higher at $8.03. A total of 11.33 million shares were traded, which is above the daily average volume of 6.32 million. The stock has gained 10.45% in the last three trading sessions and 18.26% in the last one month as compared to a gain of 1.28% and 5.69% in the S&P 500 during the respective periods. Sign up and read the complimentary report on MNKD at:

http://www.AAAResearchReports.com/MNKD080213.pdf

Galena Biopharma Inc.'s stock surged on Thursday, finishing at $2.09, up 7.18% from its previous closing price. The company's shares fluctuated between $1.95 and $2.10. A total of 2.87 million shares were traded, which is above the daily average volume of 1.86 million. The stock has gained 17.42% in the last three sessions, outperforming the S&P 500. Further, the stock is trading above its 50-day and 200-day moving averages. The free report on GALE can be downloaded by signing up now at:

http://www.AAAResearchReports.com/GALE080213.pdf

Shares in Ariad Pharmaceuticals Inc. moved higher on Thursday, tracking gains in the broader market. The company's shares traded between $18.57 and $19.04 before ending the session 2.10% higher at $18.97. A total of 1.38 million shares were traded, which is below the daily average volume of 2.17 million. The company's shares have advanced 3.21% in the last three sessions, outperforming the S&P 500. However, in the last one month, the stock has underperformed the broader market, falling by 2.87% as compared to a gain of 5.69% in the S&P 500. A free report on ARIA can be accessed by registering at:

http://www.AAAResearchReports.com/ARIA080213.pdf

Novavax Inc.'s stock edged lower on Thursday even as the broader market posted significant gains. The company's shares oscillated between $2.63 and $2.74 before finishing the day 0.37% lower at $2.68. A total of 2.03 million shares were traded, which is above the daily average volume of 1.78 million. Despite Thursday's pullback, the company's shares have gained 6.77% in the last three trading sessions, outperforming the S&P 500. Moreover, the stock is currently trading near its 52-week high of $2.78 and above its 50-day and 200-day moving averages. Register with AAA Research Reports and download research on NVAX for free at:

http://www.AAAResearchReports.com/NVAX080213.pdf

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://AAAresearchreports.com

 

 


'/>"/>
SOURCE AAA Research Reports
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Generics Analysis: Key Patent Case Reviews
2. Medical Equipment Annual Deals Analysis: M&A and Investments Trends - 2012
3. Medical Equipment Monthly Deals Analysis: February 2013 - M&A and Investment Trends
4. 2013 Cancer Diagnostics Market Analysis: Cancer Testing Industry Growing Rapidly
5. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
7. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
8. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
9. NovoBioPharma, Partnership of Top Life Science Experts, Launches
10. Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
11. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas ... Brasil as the company,s second affiliate in Latin America . ... ... of Astellas Farma Colombia ... ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
Breaking Medicine News(10 mins):